Xu ZhongChi, Qian LiChao, Niu RuGe, Yang Ying, Liu ChunLing, Lin Xin
Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Nanjing Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Front Med (Lausanne). 2022 Apr 25;9:838256. doi: 10.3389/fmed.2022.838256. eCollection 2022.
Huangqi injection (HQI) is the extract of Astragalus membranaceus (Fisch.) Bunge, which is widely used in the treatment of a variety of diseases in China. It is supposed to be an important adjuvant therapy for hypertensive nephropathy.
To evaluate the efficacy of HQI combined with antihypertensive drugs in the treatment of hypertensive nephropathy.
We systematically searched China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang Knowledge Service Platform (WanfangData), Chinese Biomedical Database (CBM), EMBASE, PubMed and Cochrane Library from their inception to April 23st, 2021. All studies were independently screened by two auditors according to the inclusion and exclusion criteria. Randomized controlled trials comparing HQI in combination with antihypertensive drugs vs. antihypertensive drugs alone were extracted.
The meta-analysis included 15 studies involving 1,483 participants.The effect of HQI combined with antihypertensive drugs is better than that of antihypertensive drugs alone in regulating hypertensive nephropathy for reducing 24-h urinary total protein (24 h UTP) [WMD=-0.29, 95% CI (-0.40, -0.18), = 0.000], microalbuminuria (mALB) [WMD = -17.04, 95% CI (-23.14, -10.94), = 0.000], serum creatinine (SCr) [WMD = -40.39, 95% CI (-70.39, -10.39), = 0.008], systolic blood pressure (SBP) [WMD = -9.50, 95% CI (-14.64, -4.37), = 0.000], diastolic blood pressure (DBP) [WMD = -4.588, 95% CI (-6.036, -3.140), = 0.000], cystatin-C (Cys-c) [WMD = -0.854, 95% CI (-0.99, -0.72), = 0.000], blood urea nitrogen (BUN) [WMD = -4.155, 95% CI (-6.152, -2.157), = 0.000].
The combination of HQI and antihypertensive drugs is more efficient in improving the related indexes of patients with hypertensive nephropathy than using antihypertensive drugs alone, and a moderate dose of HQI (no more than 30 mL) may benefit more. However, the quality of the methodology is low and the number of samples is small, the results need to be confirmed by more stringent randomized controlled trials.
黄芪注射液（HQI）是黄芪的提取物，在中国广泛用于治疗多种疾病。它被认为是高血压肾病的一种重要辅助治疗方法。
评估黄芪注射液联合降压药治疗高血压肾病的疗效。
我们系统检索了中国知网（CNKI）、维普中文科技期刊数据库（VIP）、万方知识服务平台（WanfangData）、中国生物医学文献数据库（CBM）、荷兰医学文摘数据库（EMBASE）、美国国立医学图书馆生物医学期刊数据库（PubMed）和考克兰图书馆，检索时间从建库至2021年4月23日。由两名审核员根据纳入和排除标准独立筛选所有研究。提取比较黄芪注射液联合降压药与单纯降压药的随机对照试验。
荟萃分析纳入15项研究，共1483名参与者。黄芪注射液联合降压药在调节高血压肾病以降低24小时尿总蛋白（24 h UTP）[加权均数差（WMD）=-0.29，95%置信区间（CI）（-0.40，-0.18），P = 0.000]、微量白蛋白尿（mALB）[WMD = -17.04，95% CI（-23.14，-10.94），P = 0.000]、血清肌酐（SCr）[WMD = -40.39，95% CI（-70.39，-10.39），P = 0.008]、收缩压（SBP）[WMD = -9.50，95% CI（-14.64，-4.37），P = 0.000]、舒张压（DBP）[WMD = -4.588，95% CI（-6.036，-3.140），P = 0.000]、胱抑素C（Cys-c）[WMD = -0.854，95% CI（-0.99，-0.72），P = 0.000]、血尿素氮（BUN）[WMD = -4.155，95% CI（-6.152，-2.157），P = 0.000]方面的效果优于单纯降压药。
黄芪注射液联合降压药在改善高血压肾病患者相关指标方面比单纯使用降压药更有效，中等剂量的黄芪注射液（不超过30 mL）可能更有益。然而，研究方法的质量较低且样本量较小，结果需要通过更严格的随机对照试验来证实。
Zotero 插件
